StockTipsArenaBeta

BUY Sai Parenterals Limited — Aastha Jain, Hem Securities

BUYSai Parenterals Limited
Sai Parenterals share price target & all analyst calls
○ No entry — the market opened at ₹576, above the ₹544 target

byAastha Jain, Hem SecuritiesHorizon: NA (inferred Swing (≤2wk))26 Aug 2026via Zee Business (Live)

Entry—No entry — opened past the call
Target₹544
Total upside —
Stop loss₹514—
Exit—No position was opened
ExpiredNA
Follow Aastha Jain for new calls(30% target hit, 80 closed calls)Get alertsWatch SAIPARENT for new buy/sell callsGet alertsSee 156 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 8 Sept 2026
4 supporting0 opposing
Supports the BUY call (4)

Sai Parenterals' Australian OTC supply book hits ₹1,506 crore with second contract renewal

NewsCnbc-Tv18·25 Aug · 2w ago

(opens in new tab)

Sai Parenterals Limited's subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed a long-term OTC Medicines Supply Agreement with an Australian pharmacy chain. The agreement is for 3 years, with a

NSE · Bagging/Receiving of orders/contracts·25 Aug · 2w ago

(opens in new tab)

Sai Parenterals' Australian subsidiary has renewed a 3-year OTC supply agreement with a leading Australian pharmacy network for AUD 30 million (approx. INR 204 crore). This renewal expands the product

BSE · Company Update·25 Aug · 2w ago

(opens in new tab)

Sai Parenterals' subsidiary, Noumed Pharmaceuticals Pty Limited, has renewed a long-term OTC Medicines Supply Agreement with an Australian pharmacy chain. The renewed agreement is for 3 years with a p

BSE · Company Update·25 Aug · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

More from Aastha Jain, Hem Securities

Every call and its outcome